表紙
市場調査レポート

自己免疫関連の提携条件と契約

Global Autoimmune Partnering 2010-2016: Deal Trends, Players and Financials

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 325528
出版日 ページ情報 英文 700+ Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
自己免疫関連の提携条件と契約 Global Autoimmune Partnering 2010-2016: Deal Trends, Players and Financials
出版日: 2016年07月05日 ページ情報: 英文 700+ Pages
概要

当レポートでは、自己免疫関連の提携条件と契約について調査分析し、提携取引の動向、平均取引条件、提携契約構造、提携契約書類、取引高 (金額別) 、最も積極的な契約企業などについて、体系的な情報を提供しています。

第1章 イントロダクション

第2章 自己免疫関連の契約動向

  • イントロダクション
  • 自己免疫関連の提携の推移
  • 大手製薬企業の自己免疫関連の契約活動
  • 大手バイオ企業の自己免疫関連の契約活動
  • 自己免疫関連の提携に最も積極的な企業
  • 自己免疫関連の提携:取引タイプ別
  • 自己免疫関連の提携:産業部門別
  • 自己免疫関連の提携:開発段階別
  • 自己免疫関連の提携:技術タイプ別
  • 自己免疫関連の提携:がん適応症別
  • 自己免疫関連の平均取引条件

第3章 自己免疫関連の主要取引

  • イントロダクション
  • 自己免疫関連の主要取引:金額別

第4章 大手製薬企業の自己免疫関連の取引

  • イントロダクション
  • 提携契約の活用法
  • 提携企業のプロファイル

第5章 大手バイオ企業の自己免疫関連の取引

  • イントロダクション
  • 提携契約の活用法
  • 提携企業のプロファイル

第6章 自己免疫関連の提携契約ディレクトリ

  • イントロダクション
  • 取引タイプ別
  • 開発段階別
  • 技術タイプ別

第7章 自己免疫関連の契約:適応症別

  • イントロダクション
  • 取引:適応症別

第8章 提携リソースセンター

  • オンライン提携
  • 提携イベント
  • 契約に関する関連資料

Wildwood Venturesについて

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2228

Global Autoimmune Partnering 2010 to 2016 provides the full collection of Autoimmune disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Autoimmune partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Autoimmune partnering agreement structure
  • Autoimmune partnering contract documents
  • Top Autoimmune deals by value
  • Most active Autoimmune dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.

The report includes coverage of the following autoimmune diseases:

Multiple sclerosis, Restless leg syndrome, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison's disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.

The report presents financial deal terms values for Autoimmune deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Autoimmune dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Autoimmune dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Autoimmune deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Autoimmune dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Autoimmune deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Autoimmune partnering deals by specific Autoimmune target announced since 2010. The chapter is organized by specific Autoimmune therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Autoimmune partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Autoimmune partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Autoimmune technologies and products.

Benefits

Global Autoimmune Partnering 2010 to 2016 provides the reader with the following key benefits:

  • In-depth understanding of Autoimmune deal trends since 2010
  • Access Autoimmune deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Autoimmune partner companies
  • Comprehensive access to over 500 links to actual Autoimmune deals entered into by the world's biopharma companies
  • Indepth review of Autoimmune deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Autoimmune opportunities
  • Uncover companies actively partnering Autoimmune opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Autoimmune dealmaking

  • 2.1. Introduction
  • 2.2. Autoimmune partnering over the years
  • 2.3. Autoimmune partnering by deal type
  • 2.4. Autoimmune partnering by industry sector
  • 2.5. Autoimmune partnering by stage of development
  • 2.6. Autoimmune partnering by technology type
  • 2.7. Autoimmune partnering by therapeutic indication

Chapter 3 -Financial deal terms for Autoimmune partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Autoimmune partnering
  • 3.3. Autoimmune partnering headline values
  • 3.4. Autoimmune deal upfront payments
  • 3.5. Autoimmune deal milestone payments
  • 3.6. Autoimmune royalty rates

Chapter 4 - Leading Autoimmune deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Autoimmune partnering
  • 4.3. List of most active dealmakers in Autoimmune
  • 4.4. Top Autoimmune deals by value

Chapter 5 - Autoimmune contract document directory

  • 5.1. Introduction
  • 5.2. Autoimmune partnering deals where contract document available

Chapter 6 - Autoimmune dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Autoimmune therapeutic target

Appendices

  • Appendix 1 - Directory of Autoimmune deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Autoimmune deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Autoimmune deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Autoimmune deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of Contents

Table of figures

  • Figure 1: Autoimmune partnering since 2010
  • Figure 2: Autoimmune partnering by deal type since 2010
  • Figure 3: Autoimmune partnering by industry sector since 2010
  • Figure 4: Autoimmune partnering by stage of development since 2010
  • Figure 5: Autoimmune partnering by technology type since 2010
  • Figure 6: Autoimmune partnering by indication since 2010
  • Figure 7: Autoimmune deals with a headline value
  • Figure 8: Autoimmune deals with upfront payment values
  • Figure 9: Autoimmune deals with milestone payment
  • Figure 10: Autoimmune deals with royalty rates
  • Figure 11: Active Autoimmune dealmaking activity- 2010 to 2016
  • Figure 12: Top Autoimmune deals by value since 2010
Back to Top